The primary goals of the Molecular Therapeutics (MT) Program are to study and evaluate cancer targets, develop novel chemical probes that will lead to new therapies, and devise more effective delivery systems to treat cancer. MT has highly integrated basic science and translational themes in five areas: chemical and structural biology; drug discovery and development; drug delivery and nanotechnology; systems pharmacology; and oncogenic signaling. MTs objective is to combine these elements to develop novel therapeutics and to translate innovative discoveries into applications relevant to LCCC-initiated human trials. Interactions of MT?s members with LCCC basic, translational and clinical faculty enables many of the scientific steps needed for the discovery and development of promising therapies. This includes: (1) Discovery and validation of new targets for cancer therapies, (2) Development of chemical probes to modulate and further validate identified targets, (3) Development of faithful animal cancer models for the testing of novel therapeutics, (4) Discovery and application of novel surface chemistry and nanoparticle synthesis for delivery and formulation of promising therapeutics, (5) Characterization of PK/PD of novel therapeutics involving preclinical models and patient clinical trials. The focused development of MT during the past five years provides the requisite infrastructure and knowledge-base to truly do drug discovery in an academic setting. A major strength of the program has been the enhancement of chemical biology that has benefited virtually everyone involved in cancer research at UNC and in the Cancer Center. Examples of this success are represented by LCCC investigator lead startups developing clinical-candidate MER inhibitors with potent anti- tumor activity entering phase 1 trials, and the discovery of pharmacological quiescence where a lead compound will begin Phase II testing in small cell lung cancer in early 2015. Leadership for Molecular Therapeutics is provided by Stephen Frye, Director of the Center for Integrative Chemical Biology and Drug Discovery (CICBDD) and Fred Eshelman Distinguished Professor in the UNC School of Pharmacy and Gary Johnson, the Kenan Distinguished Professor and Chair of the Department of Pharmacology in the School of Medicine. The program fosters a strong integrated research effort through the establishment, use and advancement of core facilities and promoting highly interactive collaborations with Cancer Center investigators. The Molecular Therapeutics Program consists of 42 members associated with the Schools of Medicine, Pharmacy and Arts & Sciences. During the last funding period, program members have published 700 cancer- related articles (30% collaborative). In 2014, our program members held 89 grants and $22M (total cost) in annual extramural funding, including 36 grants and $8.8M (total costs) from the NCI.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Conway, Kathleen; Edmiston, Sharon N; Parrish, Eloise et al. (2017) Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study. Breast Cancer Res Treat 163:349-361
Williams, Lindsay A; Olshan, Andrew F; Hong, Chi-Chen et al. (2017) Alcohol Intake and Breast Cancer Risk in African American Women from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 26:787-794
Quach, Bryan; Furey, Terrence S (2017) DeFCoM: analysis and modeling of transcription factor binding sites using a motif-centric genomic footprinter. Bioinformatics 33:956-963
Wang, Sheng; Wacker, Daniel; Levit, Anat et al. (2017) D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358:381-386
Westmoreland, Katherine D; Montgomery, Nathan D; Stanley, Christopher C et al. (2017) Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. Int J Cancer 140:2509-2516
Kang, SunAh; Fedoriw, Yuri; Brenneman, Ethan K et al. (2017) BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. J Immunol 198:2602-2611
Ehe, Ben K; Lamson, David R; Tarpley, Michael et al. (2017) Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1. Biochem Biophys Res Commun 491:767-772
Krishnaiah, Saikumari Y; Wu, Gang; Altman, Brian J et al. (2017) Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism. Cell Metab 25:961-974.e4
Shutova, Maria S; Asokan, Sreeja B; Talwar, Shefali et al. (2017) Self-sorting of nonmuscle myosins IIA and IIB polarizes the cytoskeleton and modulates cell motility. J Cell Biol 216:2877-2889
Evon, Donna M; Golin, Carol E; Stewart, Paul et al. (2017) Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials 57:58-68

Showing the most recent 10 out of 1197 publications